Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit
  • USA - English


News provided by

Ford & Associates Nationwide Legal Services, A.P.C.

Mar 06, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


San Diego, CA (PRWEB) March 06, 2015 -- As the Mayo Clinic's 2012 published Benicar case study findings continue to be discussed, Ford & Associates Nationwide Legal Services, A.P.C., comments on these findings in wake of a January 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in US District Court, Northern District of California.

Ford & Associates is offering free case evaluations for those individuals and their loved ones who believe they have suffered damages from Benicar use, and encourage anyone with questions for a Benicar lawyer to contact the firm.

Post this

“In light of a recently filed lawsuit, Ford & Associates encourages those who have used Benicar to evaluate and explore the Mayo Clinic's Benicar case study findings purportedly linking Benicar use and the development of sprue-like enteropathy. We encourage those who are seeking to discuss these case findings to contact us directly to speak with a qualified Benicar lawyer."

  • Mateo Martinez, Ford & Associates Case Manager

Benicar (olmesartan medoxomil) and Benicar hct (olmesartan medoxomil hydrochlorothiazide) was approved by the FDA in April 2002 for the treatment of high blood pressure due to hypertension. Patients who have taken the drug have allegedly experienced sprue-like enteropathy which can cause serious gastrointestinal issues—including chronic diarrhea, rapid weight loss, abdominal pain, vomiting, and anemia.

In January, 2015, a lawsuit was filed by Louis Verduzco and Michael Ewald against Daiichi Sankyo, maker of Benicar, and Forest Laboratories, marketer of Benicar (Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159). According to court documents, both plaintiffs allegedly suffered from adverse health conditions including sprue-like enteropathy, lymphocytic colitis, microscopic colitis, chronic diarrhea, and dehydration from using the drug. The court documents also allege that neither the plaintiffs nor their physicians were aware of any adverse olmesartan side effects associated with use of the drug.

Ford & Associates finds it important to note that in June 2012, the report of alleged Benicar side effects prompted the Mayo Clinic to conduct a Benicar case study. The findings of this study were published as a case series in Mayo Clinic Proceedings, and documented physician's findings in their response to discontinuing Benicar use in patients experiencing sprue-like enteropathy. The 22 patients studied were suffering from unexplained chronic diarrhea, dehydration, and other gastrointestinal problems—and were allegedly taking Benicar to treat high blood pressure. The patients were asked by their physicians to discontinue their use of Benicar, and after discontinuing use, the patients’ symptoms of gastrointestinal issues purportedly improved.*

In addition, Ford & Associates further notes that after multiple reports were received by the FDA’s Adverse Event Reporting System (FAERS), the FDA found “clear evidence of an association between olmesartan medoxomil and sprue-like enteropathy.” As a result, the FDA issued a Drug Safety Communication in July 2013 warning that Benicar “could cause severe intestinal damage known as sprue-like enteropathy.” This prompted a required safety alert change to Benicar's labeling.**

  • mayoclinicproceedings.org/article/S0025-6196(12)00558-7/fulltext, Mayo Clinic, August 2012

** fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf, FDA, July 2013

About Ford & Associates Nationwide Legal Services, A.P.C.
Ford & Associates Nationwide Legal Services, A.P.C., is a San Diego based injury firm that fights aggressively for the rights of those who cannot fight for themselves. Each case is treated with unparalleled dedication, competence, and skill, and pursued to the fullest extent as allowed by law until a favorable outcome has been reached.

If you or a loved one believe that you have suffered adverse health conditions from using Benicar, and would like answers to Benicar lawsuit questions, contact Ford & Associates today at 1-866-242-0905 for a free, no-obligation case review.

Ford & Associates Nationwide Legal Services, A.P.C.
3555 4th Ave
San Diego, CA 92103
866-242-0905

ATTORNEY ADVERTISING. Ford & Associates Nationwide Legal Services, APC. This is an attorney advertisement. The information in this article is only provided for general information purposes. The information presented in this article and your viewing of the information in this article does not establish an attorney-client relationship. If you need legal assistance, we encourage you to call, write or email us. By contacting us, an attorney-client relationship has not been created. A formal attorney client-client relationship is not established until you have signed a retainer agreement and your case has been accepted. Please do not send any documents, evidence or any other information relating to your case until an attorney-client relationship has been established. Prior results do not guarantee a similar outcome with respect to any future matter. Please call or email our firm for a free, no obligation case evaluation.

Contact Information:
Mateo Martinez, Case Manager
Ford & Associates Nationwide Legal Services, A.P.C.
3555 4th Ave
San Diego, CA 92103
866-242-0905
drug-lawsuits.com

Mateo Martinez, Ford & Associates Nationwide Legal Services, A.P.C., http://drug-lawsuits.com, +1 866-242-0905, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.